Eva Corey

Proteomic Characterization of Prostate Cancer Bone Metastasis Subtypes Defines Progressive Remodeling States of the Bone-Tumor Microenvironment

This study identifies proteomic signatures of prostate cancer bone metastasis subtypes, revealing distinct molecular states of bone-tumor microenvironment remodeling.

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

This study identifies a functional cooperation between nuclear pore complexes and m6A signaling that promotes castration-resistant prostate cancer by linking mRNA export to cholesterol biosynthesis and androgen production.

FOXJ1 mediates taxane resistance through regulation of microtubule dynamics

This paper identifies FOXJ1 as a mediator of taxane resistance in prostate cancer by regulating microtubule dynamics, with clinical implications for patient stratification.

Global mRNA 3'UTR lengthening in small-cell neuroendocrine carcinoma

The paper identifies global 3'UTR lengthening in SCNC through APA and develops a neural network model to classify SCNC using APA signatures.

Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer

This study shows that AR inhibition does not enhance PARP inhibitor efficacy in HR-proficient prostate cancer and instead impairs response in castration-sensitive cells.

TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer

This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.

Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer

The paper identifies a subgroup of mCRPC characterized by LINE1 repeat DNA elements flanking the AR gene, which drive AR overexpression and confer resistance to androgen signaling inhibitors.

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.

This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

Imaging and quantification of prostate cancer-associated bone by polarization-sensitive optical coherence tomography

This study uses PS-OCT to differentiate bone tissue types in prostate cancer metastases by analyzing collagen organization and quantifying structural features.

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

This study shows MYC overexpression disrupts AR transcriptional pause release, promoting aggressive prostate cancer progression.